Tumour response endpoints in the BA1112 rat sarcoma

Area of Science:

• Oncology
• Radiation Oncology
• Tumor Biology

Background:

• The BA1112 rat rhabdomyosarcoma is a well-established, transplantable tumor model.
• It is isologous to WAG/Rij rats, exhibiting no host immune response and limited metastasis.
• This model is known to contain hypoxic cells that reoxygenate during fractionated radiation therapy.

Purpose of the Study:

• To evaluate the BA1112 rat rhabdomyosarcoma as a model for radiation therapy research.
• To analyze the in vivo response of this tumor to fractionated radiation therapy.
• To investigate cellular response, reoxygenation, and proliferation in the context of radiation treatment.

Main Methods:

• Utilizing the BA1112 rat rhabdomyosarcoma as an in vivo model.
• Employing a newly developed in vitro assay for tumor cell clonogenicity.
• Measuring radiation dose-response curves and monitoring cellular response post-treatment.

Main Results:

• The BA1112 model demonstrates stable growth and radiation response characteristics over 15 years.
• Hypoxic cells within the tumor undergo reoxygenation during fractionated radiation therapy.
• The in vitro clonogenicity assay facilitates efficient monitoring of radiation effects.

Conclusions:

• The BA1112 rat rhabdomyosarcoma is a robust and reliable model for radiation therapy studies.
• Understanding reoxygenation dynamics in hypoxic tumors is crucial for effective radiation treatment planning.
• This model aids in analyzing cellular mechanisms underlying tumor response to fractionated radiotherapy.